AP-Brain Collagen Peptide
Dietary SupplementSingle dose once daily
NCT Number: NCT07572240
The goal of this clinical trial is to learn about the effects of AP-Brain collagen peptide on attention, focus, and memory in adults who are stressed but otherwise healthy.
The main questions it aims to answer are:
* How does AP-Brain affect a participant's attention, focus, stress, and memory? * Is there a difference in the effects between a higher dose and a lower dose? * What are the side effects, if any, for participants taking AP-Brain?
Researchers will compare two different doses of AP-Brain to see how they affect brain function and stress levels.
Participants in this study will be asked to:
* Take one of two the doses of AP-Brain once a day for 56 days. * Visit the study center for regular checkups. * Complete tasks that measure memory, focus, and attention. * Answer survey questions about their stress levels. * Provide blood samples and have vital signs checked. * Have the brain's response to tasks monitored to see how it affects attention and alertness.
Interested in participating?
Request InfoHealthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dose once daily
Time frame: Baseline and Day 56
The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference.
The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test.
Time frame: Baseline and Day 28
The Stroop Color Word Test is a validated neuropsychological assessment used to measure selective attention, cognitive flexibility, processing speed, and executive control. The test requires participants to identify the ink color of printed words that may represent incongruent color names, thereby assessing the ability to inhibit automatic responses and manage cognitive interference
The change in selective attention and focus will be measured by change in mean reaction time (ms) and stroop latency by Stroop Color-Word test.
Time frame: Baseline, Day 28, and Day 56
The CPT measures sustained attention of participants to predefined target sequence in two phases (Phase X where participant has to respond to target "X" and phase AX where participant has to respond to target "AX" (e.g., "A" followed by "X") and withhold responses to non-target sequences.
The change in sustained attention is measured through change in mean response time (ms), omission rates (xtestomissionerrorrate during phase X and axtestomissionerrorrate during phase AX), commission rates (xtestcomissionerrorrate during phase X and axtestcomissionerrorrate during phase AX).
Time frame: Baseline, Day 28, and Day 56
The Digit Span Test is a standardized neuropsychological measure used to assess working memory capacity and attentional control. It includes two components: Digit Span Forward, in which individuals repeat a sequence of numbers in the same order as presented, and Digit Span Backward, in which they recall the numbers in reverse order.
The change in memory will be measured by change of maximum digit span the longest correctly recalled sequence length (fML: maximal forward span; bML: maximal backward span) and the mean span, defined as the list length at which 50% of sequences are correctly recalled (fMS: expected forward span correct 50% of the time across 14 trials; bMS: expected backward span correct 50% of the time across 14 trials).
Time frame: Baseline, Day 28, and Day 56
The PSS is a 10-item questionnaire with a recall period of 1 month, designed to examine participants' self-reported levels of stress during the past month by examining their thoughts and feelings. Each question is rated on a scale of 0 (never) to 4 (very often). The PSS provides a total score out of 40, where a higher score indicates higher levels of self-perceived stress.
Time frame: Baseline and Day 56
Event-related potentials will be elicited using a standard P300 paradigm. P3b latency and P3b amplitude will be quantified.
P3b latency will be defined as time internal (milliseconds) from stimulus onset to the maximum positive peak within expected P300 time window.
P3b amplitude will be measured as the voltage difference (microvolts) between baseline and the peak of the P3b component.
Time frame: Baseline and 1 hour post-dose Day 56
Change of BDNF levels to determine acute neurotrophic response and synaptic plasticity via blood sample collection.
Time frame: Baseline and 1 hour post-dose Day 56
Change in ratio of cortisol/DHEAS levels to determine stress via blood sample collection.
Time frame: Baseline and 1 hour post-dose Day 56
Change of TNF-α levels to determine inflammation via blood sample collection.
Time frame: Baseline and 1 hour post-dose Day 56
Change of MDA levels to determine systemic oxidative stress via blood sample collection.
Time frame: Baseline and Day 56
Change in cognition status will be assessed using the ACE-III. The ACE-III provides a total score out of 100, where a higher score indicates better cognitive function. The assessment covers five cognitive domains of orientation/attention, memory, fluency, language, and visuospatial function.
Time frame: Baseline and 1 hour post-dose Day 56
Change of cGP levels via blood sample collection.
Time frame: Baseline and 1 hour post-dose Day 56
Change of IGF-1 levels via blood sample collection.
Time frame: Baseline, Day 28, and Day 56
Change in vitals assessed through blood pressure with units of mmHg.
Time frame: Baseline and 1 hour post-dose Day 56
Safety of test product assessed by liver function test obtained via blood sample. The liver function test will include evaluation of aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total bilirubin, and total proteins.
Time frame: Baseline, Day 28, and Day 56
Change in vitals assessed through pulse rate to provide beats per minute (bpm).
Time frame: Baseline and 1 hour post-dose Day 56
Safety of test product assessed by complete blood count obtained via blood sample. The complete blood count will include evaluation of hematocrit, hemoglobin, platelet, red blood cell count, white blood cell count, neutrophil, lymphocyte, monocyte, eosinophil, and basophil.
Time frame: Baseline and 1 hour post-dose Day 56
Safety of test product assessed by fasting blood glucose levels obtained via blood sample.
Contact information is provided by the study sponsor or research team.
Rousselot BVBA
Industry
A Randomized, Open-Label, Parallel Proof-of-Concept Study to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06690866
Healthy, Puberty
Tübingen, Baden-Wurttemberg, Germany
View Trial DetailsNCT06870669
Behavior, Exercise
Manisa, Yunusemre, Turkey (Türkiye)
View Trial DetailsNCT07024901
Anxiety, Anxiety Disorders
Vilnius, Lithuania
View Trial DetailsNCT05738746
Dietary Supplement, Healthy
Szczecin, West Pomeranian Voivodeship, Poland
View Trial Details